BD/Haselmeier
This article was originally published in The Gray Sheet
Executive Summary
BD inks agreement with Germany-based Haselmeier GmbH to form a joint venture for the design, development and exclusive distribution of auto-injecting pen devices, the companies announce Oct. 5. The Swiss-based venture, BD/Medico GmbH, will design hidden-needle injection devices for the self-administration of parenteral drugs. BD is targeting recipients of growth hormones, fertility agents, alpha-interferon for hepatitis, beta-interferon for multiple sclerosis and low molecular weight heparin for deep vein thrombosis. While the devices will be immediately available to pharmaceutical companies, BD estimates a timeframe of 18-24 months before the devices make it to the U.S. market
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.